GlycoMimetics (NASDAQ:GLYC) is a clinical‐stage biotechnology company headquartered in Rockville, Maryland, that specializes in the discovery and development of glycomimetic therapeutics. Founded in 2003, the company leverages its proprietary carbohydrate mimic platform to design small molecules that interfere with key cell adhesion processes. By targeting selectin-mediated interactions between cells and blood vessel walls, GlycoMimetics aims to address unmet medical needs in oncology, hematology, and inflammatory diseases.
The company’s lead candidate, uproleselan (GMI-1271), is designed to block E-selectin in the bone marrow microenvironment, enhancing the efficacy of chemotherapy in acute myeloid leukemia and other hematologic malignancies. In parallel, GlycoMimetics is developing GMI-1687, a highly potent E-selectin inhibitor intended for subcutaneous administration in sickle cell disease, where it seeks to reduce vaso‐occlusive crises by preventing red blood cell adhesion. Additional pipeline assets explore P- and L-selectin inhibition for inflammatory conditions and solid tumor metastasis.
Throughout its history, GlycoMimetics has established collaborations with leading pharmaceutical partners to advance its clinical programs and expand its research capabilities. The company operates primarily in the United States but engages with global clinical sites for multi‐center trials. Research and development facilities in the Mid‐Atlantic region support medicinal chemistry, pharmacology, and translational science efforts, while regulatory teams coordinate submissions with agencies in North America, Europe, and other key markets.
GlycoMimetics is led by an experienced management team with deep expertise in drug development and biotechnology. Rachel King serves as President and Chief Executive Officer, bringing over two decades of leadership in life sciences. The executive team includes seasoned professionals in clinical operations, regulatory affairs, and corporate development. Guided by a scientific advisory board of experts in glycobiology and hematology, GlycoMimetics continues to advance its glycomimetic strategy toward transformative therapies for patients worldwide.
